The results of this work will serve as a basis for further structural studies of G0S2 and the G0S2-ATGL interaction, providing significant information that helps develop future therapeutics for NAFLD treatment. The gene discussed is G0S2; the disease is metabolic dysfunction-associated steatotic liver disease.